File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Loss of HBsAg in nucleoside-naive HBeAg(+) chronic hepatitis B patients following treatment with entecavir or lamivudine: evaluation of HBV genotypes

TitleLoss of HBsAg in nucleoside-naive HBeAg(+) chronic hepatitis B patients following treatment with entecavir or lamivudine: evaluation of HBV genotypes
Authors
Issue Date2009
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
The American Assoication for the Study of Liver Diseases 60th Annual Meeting and Postgraduate Course - The Liver Meeting, Boston, MA, 30 October - 3 November 2009. In Hepatology, 2009, v. 50 n. 4 Suppl, p. 487A-488A Abstract no. 388 How to Cite?
AbstractBACKGROUND: Spontaneous HBsAg seroclearance has beenestimated to occur at a rate of 0.5 to 1.7% per year. In thephase III study ETV-022, 5.1% of nucleoside-naïve HBeAg(+)chronic hepatitis B (CHB) patients treated with entecavir (ETV)had confirmed HBsAg loss by week 120. In this analysis weevaluated the distribution of confirmed HBsAg loss according tothe hepatitis B virus (HBV) genotype in patients treated with ETVor lamivudine (LVD) in study ETV-022. METHODS: HBeAg(+) nucleoside-naïve adults with CHB, elevated serum alanineaminotransferase (ALT), and compensated liver disease wererandomized to double-blind treatment for up to 96 weeks withETV 0.5 mg/day or LVD 100 mg/day, with up to 24 weeks ofoff-treatment follow-up. HBsAg was measured at regular inter-vals during on- and off-treatment follow-up. For this analysis,confirmed HBsAg loss was defined as HBsAg loss documentedon two consecutive measurements or at last observation,regardless of treatment period. RESULTS: A total of 18 of 354(5.1%) ETV-treated patients and 10/355 (2.8%) LVD-treatedpatients had confirmed HBsAg loss by week 120. Of the 18ETV patients with HBsAg loss, 8 were genotype A, 2 genotypeB, 1 genotype C, 5 genotype D, and 2 genotype F. A higherproportion of patients infected with HBV genotype A or geno-type D lost HBsAg (8.4% and 13.5% respectively) comparedwith patients infected with genotype B or C (2.9% and 0.9%respectively). Similar patterns were observed among the 10LVD-treated patients. Combining both ETV- and LVD-treatedpatients, those infected with HBV genotype A or D were morelikely to lose HBsAg (7.7% and 8.1% respectively) comparedwith patients infected with genotype B or C (2.1% and 0.5%respectively). CONCLUSIONS: Among all patients treated withETV or LVD in study ETV-022, patients infected with HBV geno-type A or D had a higher rate of HBsAg loss than patients withgenotype B or C infection in both treatment arms. Overall,patients treated with ETV had a higher rate of HBsAg lossacross most HBV genotypes compared with LVD-treatedpatients.
Persistent Identifierhttp://hdl.handle.net/10722/224430
ISSN
2015 Impact Factor: 11.711
2015 SCImago Journal Rankings: 4.752

 

DC FieldValueLanguage
dc.contributor.authorGish, RG-
dc.contributor.authorChang, TT-
dc.contributor.authorLai, CL-
dc.contributor.authorDe Man, RA-
dc.contributor.authorPoordad, F-
dc.contributor.authorXu, D-
dc.contributor.authorBrett-Smith, H-
dc.contributor.authorHarris, M-
dc.contributor.authorIloeje, U-
dc.contributor.authorTang, H-
dc.date.accessioned2016-04-05T04:10:41Z-
dc.date.available2016-04-05T04:10:41Z-
dc.date.issued2009-
dc.identifier.citationThe American Assoication for the Study of Liver Diseases 60th Annual Meeting and Postgraduate Course - The Liver Meeting, Boston, MA, 30 October - 3 November 2009. In Hepatology, 2009, v. 50 n. 4 Suppl, p. 487A-488A Abstract no. 388-
dc.identifier.issn0270-9139-
dc.identifier.urihttp://hdl.handle.net/10722/224430-
dc.description.abstractBACKGROUND: Spontaneous HBsAg seroclearance has beenestimated to occur at a rate of 0.5 to 1.7% per year. In thephase III study ETV-022, 5.1% of nucleoside-naïve HBeAg(+)chronic hepatitis B (CHB) patients treated with entecavir (ETV)had confirmed HBsAg loss by week 120. In this analysis weevaluated the distribution of confirmed HBsAg loss according tothe hepatitis B virus (HBV) genotype in patients treated with ETVor lamivudine (LVD) in study ETV-022. METHODS: HBeAg(+) nucleoside-naïve adults with CHB, elevated serum alanineaminotransferase (ALT), and compensated liver disease wererandomized to double-blind treatment for up to 96 weeks withETV 0.5 mg/day or LVD 100 mg/day, with up to 24 weeks ofoff-treatment follow-up. HBsAg was measured at regular inter-vals during on- and off-treatment follow-up. For this analysis,confirmed HBsAg loss was defined as HBsAg loss documentedon two consecutive measurements or at last observation,regardless of treatment period. RESULTS: A total of 18 of 354(5.1%) ETV-treated patients and 10/355 (2.8%) LVD-treatedpatients had confirmed HBsAg loss by week 120. Of the 18ETV patients with HBsAg loss, 8 were genotype A, 2 genotypeB, 1 genotype C, 5 genotype D, and 2 genotype F. A higherproportion of patients infected with HBV genotype A or geno-type D lost HBsAg (8.4% and 13.5% respectively) comparedwith patients infected with genotype B or C (2.9% and 0.9%respectively). Similar patterns were observed among the 10LVD-treated patients. Combining both ETV- and LVD-treatedpatients, those infected with HBV genotype A or D were morelikely to lose HBsAg (7.7% and 8.1% respectively) comparedwith patients infected with genotype B or C (2.1% and 0.5%respectively). CONCLUSIONS: Among all patients treated withETV or LVD in study ETV-022, patients infected with HBV geno-type A or D had a higher rate of HBsAg loss than patients withgenotype B or C infection in both treatment arms. Overall,patients treated with ETV had a higher rate of HBsAg lossacross most HBV genotypes compared with LVD-treatedpatients.-
dc.languageeng-
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/-
dc.relation.ispartofHepatology-
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.-
dc.rightsSpecial Statement for Preprint only Before publication: 'This is a preprint of an article accepted for publication in [The Journal of Pathology] Copyright © ([year]) ([Pathological Society of Great Britain and Ireland])'. After publication: the preprint notice should be amended to follows: 'This is a preprint of an article published in [include the complete citation information for the final version of the Contribution as published in the print edition of the Journal]' For Cochrane Library/ Cochrane Database of Systematic Reviews, add statement & acknowledgement : ‘This review is published as a Cochrane Review in the Cochrane Database of Systematic Reviews 20XX, Issue X. Cochrane Reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the Review.’ Please include reference to the Review and hyperlink to the original version using the following format e.g. Authors. Title of Review. Cochrane Database of Systematic Reviews 20XX, Issue #. Art. No.: CD00XXXX. DOI: 10.1002/14651858.CD00XXXX (insert persistent link to the article by using the URL: http://dx.doi.org/10.1002/14651858.CD00XXXX) (This statement should refer to the most recent issue of the Cochrane Database of Systematic Reviews in which the Review published.)-
dc.titleLoss of HBsAg in nucleoside-naive HBeAg(+) chronic hepatitis B patients following treatment with entecavir or lamivudine: evaluation of HBV genotypes-
dc.typeConference_Paper-
dc.identifier.emailLai, CL: hrmelcl@hku.hk-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.doi10.1002/hep.23301-
dc.identifier.hkuros181234-
dc.identifier.volume50-
dc.identifier.issue4 Suppl-
dc.identifier.spage487A-
dc.identifier.epage488A Abstract no. 388-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats